A novel molecular mechanism for anticancer drug-induced ovarian failure: Irinotecan HCl, an anticancer topoisomerase I inhibitor, induces specific FasL expression in granulosa cells of large ovarian follicles to enhance follicular apoptosis

International Journal of Oncology

Volumn 32, Issue 5, 2008, Pages 991-1000

  Utsunomiya, Tomoko ^a   Tanaka, Tetsuji ^a   Utsunomiya, Hirotoshi ^a   Umesaki, Naohiko ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Apoptosis; Fas; Fas ligand; Granulosa cell; Irinotecan; Ovarian failure; Topoisomerase I inhibitor

Indexed keywords

CASPASE 3; DNA TOPOISOMERASE INHIBITOR; FAS ANTIGEN; FAS LIGAND; IRINOTECAN; RECOMBINANT PROTEIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CASP3 PROTEIN, MOUSE; DNA TOPOISOMERASE; DRUG DERIVATIVE; ENZYME INHIBITOR; FASL PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CANCER COMBINATION CHEMOTHERAPY; CELL COUNT; CELL DIFFERENTIATION; CELL LINEAGE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME DEGRADATION; FEMALE; GRANULOSA CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUTEAL CELL; MOUSE; NICK END LABELING; NONHUMAN; ORGAN CULTURE; OVARY FOLLICLE CELL; OVARY INSUFFICIENCY; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; IMMUNOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; ORGAN CULTURE TECHNIQUE; PATHOLOGY; PREMATURE OVARIAN FAILURE; UPREGULATION;

ANIMALS; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CAMPTOTHECIN; CASPASE 3; DISEASE MODELS, ANIMAL; DNA TOPOISOMERASES, TYPE I, EUKARYOTIC; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME INHIBITORS; FAS LIGAND PROTEIN; FEMALE; GRANULOSA CELLS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INJECTIONS, INTRAPERITONEAL; MICE; ORGAN CULTURE TECHNIQUES; OVARIAN FAILURE, PREMATURE; RECOMBINANT PROTEINS; UP-REGULATION;

EID: 45849151738     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.32.5.991     Document Type: Article

References (43)

1. Yuan W and Giudice LC: Programmed cell death in human ovary is a function of follicle and corpus luteum status. J Clin Endocrinol Metab 82: 3148-3155, 1997.
2. Matikainen T, Perez GI, Zheng TS, Kluzak TR, Rueda BR, Flavell RA and Tilly JL: Caspase 3 gene knockout defines cell lineage specificity for programmed cell death signaling in the ovary. Endocrinology 142: 2468-2480, 2001.
3. Jiang JY, Cheung CK, Wang Y and Tsang BK: Regulation of cell death and cell survival gene expression during ovarian follicular development and atresia. Front Biosci 8: 222-237, 2003.
4. Rivkees SA and Crawford JD: The regulationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA 259: 2123-2125, 1988.
5. Tilly JK and Kolesnick RN: Sphingolipids, apoptosis, cancer treatments and the ovary: investigating a crime against female fertility. Biochim Biophys Acta 1585: 135-138, 2002.
6. Takizawa K, Yokoo I, Shima Y, Inou Y, Sato M, Iguchi T and Takeda Y: Quantitative evaluation for murine oocyte toxicity following intraperitoneal treatment with chemotherapeutic agents. Jpn J Obstet Gynecol 41: 715-722, 1989.
7. Shiromizu K, Thorgeirsson SS and Mattison DR: Effect of cyclophosphamide on oocyte and follicle number in Sprague-Dawley rats, C57BL/6N and DBA/ 2N mice. Pediatr Pharmacol 4: 213-221, 1984.
8. Horning SJ, Hoppe RT, Kaplan HS and Rosenberg SA: Female reproductive potential after treatment for Hodgkin's disease. N Eng J Med 304: 1377-1381, 1981.
9. Kawato Y, Aonuma M, Hirota Y, Kuga H and Sato K: Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51: 4187-4192, 1991.
10. Sugiyama T, Yakushiji M, Noda K, Ikeda M, Kudoh R, Yajima A, Tomoda Y, Terashima Y, Takeuchi S, Hiura M, Saji F, Takahashi T, Umesaki N, Sato S, Hatae M and Ohashi Y: Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer. Oncology 58: 31-37, 2000.
11. Umesaki N, Fujii T, Nishimura R, Tanaka T, Nishida M, Fushiki H, Takizawa K, Yamamoto K, Hasegawa K and Izumi R: Phase II study of irinotecan combined with mitomycin-C for advanced or recurrent squamous cell carcinoma of the uterine cervix: the JGOG study. Gynecol Oncol 95: 127-132, 2004.
12. Tanaka T, Kokawa K and Umesaki N: Preoperative chemotherapy with irinotecan and mitomycin for FIGO stage IIIb cervical squamous cell carcinoma: A pilot study. Eur J Gynaecol Oncol 26: 605-607, 2005.
13. Tanaka T, Umesaki N and Ogita S: Camptothecin and mitomycin combination chemotherapy on ovarian clear cell carcinoma with multiple systemic metastases. Eur J Gynaecol Oncol 11: 377-379, 2000.
14. Nishino K, Aoki Y, Amikura T, Obata H, Sekine M, Yahata T, Fujita K and Tanaka K: Irinotecan hydrochloride (CPT-11) and mitomycin C as the first line chemotherapy for ovarian clear cell adenocarcinoma. Gynecol Oncol 97: 893-897, 2005.
15. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S and Saijo N: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Eng J Med 346: 85-91, 2002.
16. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL and Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic cororectal cancer. N Eng J Med 343: 905-914, 2000.
17. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alaki M, Gruia G, Awad L and Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 355: 1041-1047, 2000.
18. Yamao T, Shirao K, Matsumura Y, Muro K, Yamada Y, Goto M, Chin K and Shimada Y: Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer. Ann Oncol 12: 1729-1735, 2001.
19. Tobinai K and Hotta T: Clinical trials for malignant lymphoma in Japan. Jpn J Clin Oncol 34: 369-378, 2004.
20. Itabashi M, Inoue T, Amano Y and Sato K: Reproduction and developmental toxicity studies of CPT-11. Clin Res 24: 85-96, 1990.
21. Tanaka T, Umesaki N and Ogita S: Effects of shakuyaku-kanzoto on menopausal symptoms in an ovarian cancer patient treated with irinotecan HCI. J Tradit Med 15: 456-457, 1998.
22. Tanaka T, Utsunomiya T, Utsunomiya H and Umesaki N: Irinotecan HC1, an anticancer topoisomerase I inhibitor, frequently induces ovarian failure in premenopausal and perimenopausal women. Oncol Rep (In press).
23. Pederson T and Peters H: Proposal for classification of oocytes and follicles in the mouse ovary. J Reprod Fertil 17: 555-557, 1968.
24. Hakuno N, Koji T, Yano T, Kobayashi N, Tsutsumi O, Taketani Y and Nakane PK: Fas/Apo-1/CD95 system as a mediator of granulose cell apoptosis in ovarian follicle atresia. Endocrinology 137: 1938-1948, 1996.
25. Xu JP, Li X, Sato E, Saito S, Guo MW and Mori T: Expression of Fas-Fas ligand system associated with atresia in murine ovary. Zygote 5: 321-327, 1997.
26. Kim JM, Boone DL, Auyeung A and Tsang BK: Granulosa cell apoptosis induced at the penultimate stage of follicular development is associated with increased levels of Fas and Fas ligand in the rat ovary. Biol Reprod 58: 1170-1176, 1998.
27. Porter DA, Harman RM, Cowan RG and Quirk SM: Relationship of Fas ligand expression and atresia during bovine follicle development. Reproduction 121: 561-566, 2001.
28. Dharma SJ, Kelkar RL and Nandedkar TD: Fas and Fas ligand protein and mRNA in normal and atretic mouse ovarian follicles. Reproduction 126: 783-789, 2003.
29. Fenwick MA and Hurst PR: Immunohistochemical localization of active caspase-3 in the mouse ovary: growth and atresia of small follicles. Reproduction 124: 659-665, 2002.
30. Kaipia A, Chun SY, Eisenhauer K and Hsueh AJ: Tumor necrosis factor-alpha and its second messenger, ceramide, stimulate apoptosis in cultured ovarian follicles. Endocrinology 137: 4864-4870, 1996.
31. Quirk SM, Porter DA, Huber SC and Cowan RG: Potentiation of Fas-mediated apoptosis of granulosa cells by interferon-gamma, tumor necrosis factor-alpha, and cycloheximide. Endocrinology 139: 4860-4869, 1998.
32. Basini G, Mainardi GL, Bussolati S and Tamanini C: Steroidgenesis, proliferation and apoptosis in bovine granulose cells: role of tumour necrosis factor-alpha and its possible signaling mechanisms. Reprod Fertil Dev 14: 141-150, 2002.
33. Tilly JL: Apoptosis and ovarian function. Rev Reprod 1: 162-172, 1996.
34. Sasson R, Tajima K and Amsterdam A: Glucocorticoids protect against apoptosis induced by serum deprivation, cyclic adenosine 3′, 5′-monophosphate and p53 activation in immunortalized human granulose cells: involvement of bcl-2. Endocrinology 142: 802-811, 2001.
35. Sasson R and Amsterdam A: Stimulation of apoptosis in human granulosa cells from in vitro fertilization patients and its prevention by dexamethasone: involvement of cell contact and Bcl-2 expression. J Clin Endocrinol Metab 87: 3441-3451, 2002.
36. Choi D, Hwang S, Lee E, Yoon S, Yoon BK and Bae D: Expression of mitochondria-dependent apoptosis genes (p53, Bax, Bcl-2) in rat granulosa cells during follicular development. J Soc Gynecol Invest 11: 311-317, 2004.
37. Pepling ME and Spradling AC: Mouse ovarian germ cell cysts undergo programmed breakdown to form primordial follicles. Dev Biol 234: 339-351, 2001.
38. De Bruin JP, Dorland M, Spek ER, Posthuma G, van Haaften M, Looman CW and te Velde ER: Ultrastructure of the resting ovarian follicle pool in healthy young women. Biol Reprod 66: 1151-1160, 2002.
39. Boone DL and Tsang BK: Caspase-3 in the rat ovary: localization and possible role in follicular atresia and luteal regression. Biol Reprod 58: 1533-1539, 1998.
40. Yonehara S, Ishii A and Yonehara M: A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 169: 1747-1756, 1989.
41. Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV and Boldin MP: Tumor necrosis factor receptor and Fas signaling mechanisms. Ann Rev Immunol 17: 331-367, 1999.
42. Suda T, Takahashi T, Golstein P and Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75: 1169-1178, 1993.
43. Nagata S and Suda T: Fas and fas ligand: lpr and gld mutations. Immunol Today 16: 39-43, 1995.